v3.25.4
Contingencies and Environmental Liabilities (Details)
$ in Millions
1 Months Ended 2 Months Ended 5 Months Ended 6 Months Ended 12 Months Ended
Mar. 13, 2025
Dec. 19, 2022
Apr. 30, 2025
patent
Aug. 31, 2024
case
Dec. 31, 2023
case
Jun. 30, 2023
May 31, 2023
patent
Oct. 31, 2024
patent
Nov. 30, 2025
patent
Dec. 31, 2025
USD ($)
case
company
Sep. 19, 2025
Jun. 30, 2025
patent
Mar. 11, 2025
case
Dec. 31, 2024
USD ($)
Loss Contingencies [Line Items]                            
Loss contingency, joint stipulation response period                     15 days      
Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag                   liabilities        
Accrued liabilities for environmental matters | $                   $ 42       $ 41
Term for paying off environmental liabilities                   15 years        
Aggregate possible expenditure on environmental matters in excess of amounts accrued | $                   $ 58        
Legal Defense Costs                            
Loss Contingencies [Line Items]                            
Legal defense costs reserve | $                   $ 245       $ 225
Pending Litigation | Patents - PGR Petition                            
Loss Contingencies [Line Items]                            
Number of patents allegedly infringed     12                      
Dr. Scholl's | United States | Pending Litigation                            
Loss Contingencies [Line Items]                            
Loss contingency, pending claims | case                   610        
Gardasil/Gardasil 9 | United States | Pending Litigation                            
Loss Contingencies [Line Items]                            
Loss contingency, pending claims | case                   135        
Gardasil/Gardasil 9 | United States | Motion for Summary Judgement Granted                            
Loss Contingencies [Line Items]                            
Loss contingency, pending claims | case                         16  
Gardasil/Gardasil 9 | Int’l | Pending Litigation                            
Loss Contingencies [Line Items]                            
Loss contingency, pending claims | case                   15        
Zetia | United States | Pending Litigation                            
Loss Contingencies [Line Items]                            
Loss contingency, number of cases remanded | case         4                  
Bravecto | United States                            
Loss Contingencies [Line Items]                            
Loss contingency, number of statewide classes for certification | case       5                    
Bridion | Patents                            
Loss Contingencies [Line Items]                            
Loss contingency, claims settled, number of companies | company                   5        
Bridion | Pending Litigation | Patents                            
Loss Contingencies [Line Items]                            
Loss contingency, trial period   1 day                        
Bridion | Settled Litigation | Patents                            
Loss Contingencies [Line Items]                            
Patent extension, term 5 years         5 years                
Pediatric exclusivity, term 6 months                          
Januvia, Janumet, Janumet XR | Settled Litigation                            
Loss Contingencies [Line Items]                            
Loss contingency, companies settled with, minimum number | company                   24        
Keytruda | Pending Litigation | Patents                            
Loss Contingencies [Line Items]                            
Number of patents allegedly infringed             9 9            
Number of additional patents unpatentable                 9          
Subcutaneous Pembrolizumab | Pending Litigation | Patents                            
Loss Contingencies [Line Items]                            
Loss contingency, pending claims                       1    
Number of patents allegedly infringed     15                      
Subcutaneous Pembrolizumab | Pending Litigation | Patents - PGR Petition                            
Loss Contingencies [Line Items]                            
Loss contingency, pending claims                       13    
Subcutaneous Pembrolizumab | Pending Litigation | PGR Petition Process, Ineligible to be Challenged                            
Loss Contingencies [Line Items]                            
Loss contingency, pending claims     3